# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $12 to $14.
Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Strong Buy and raises the price target fro...
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...